| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Historical Perspective of Mergers in the US Pharmaceutical Industry
|
Farmer, Kevin C.
|
|
1992
|
26 |
3 |
p. 411-419
|
artikel
|
| 2 |
An Overview of Liability for OTC Drugs
|
Alsobrook, Henry B.
|
|
1992
|
26 |
3 |
p. 317-328
|
artikel
|
| 3 |
A Quantified Internal Audit System Allowing Quality Rating of Clinical Research
|
Desgouilles, R.
|
|
1992
|
26 |
3 |
p. 379-388
|
artikel
|
| 4 |
Are Initiatives to Speed the New Drug Approval Process Working?
|
Kaitin, Kenneth I.
|
|
1992
|
26 |
3 |
p. 341-349
|
artikel
|
| 5 |
Bioavailability Testing of Medicinal Products and Harmonization of International Testing Requirements and Standards: The Canadian Perspective
|
McGilveray, Iain J.
|
|
1992
|
26 |
3 |
p. 365-369
|
artikel
|
| 6 |
Clinical Packaging: Adhesives and Inks
|
Bergelson, Alan
|
|
1992
|
26 |
3 |
p. 389-393
|
artikel
|
| 7 |
Good Biometric Practice Proposals for a Set of Procedures
|
Spriet, Alain
|
|
1992
|
26 |
3 |
p. 405-409
|
artikel
|
| 8 |
Heightened Need for Information Exchange in Geriatrics
|
Lamy, Peter P.
|
|
1992
|
26 |
3 |
p. 329-332
|
artikel
|
| 9 |
Logistics-Based Approaches to Reducing Clinical Development Times
|
Edwards, Martin W.
|
|
1992
|
26 |
3 |
p. 425-432
|
artikel
|
| 10 |
NDA Day Strategy and Success for ICI Pharmaceuticals Group's Diprivan® (PROPOFOL)
|
Acosta, Gustavo
|
|
1992
|
26 |
3 |
p. 457-462
|
artikel
|
| 11 |
Practical Issues in Design and Management of Multinational Trials
|
Suwelack, Dirk
|
|
1992
|
26 |
3 |
p. 371-378
|
artikel
|
| 12 |
Reducing Barriers to the Utilization of Literature at Hoffmann-La Roche
|
Harrison, Lauren D.
|
|
1992
|
26 |
3 |
p. 433-443
|
artikel
|
| 13 |
Regulatory Requirements and Practices for Clinical Studies in Japan
|
Murao, Noriaki
|
|
1992
|
26 |
3 |
p. 333-339
|
artikel
|
| 14 |
Software Survey Section
|
|
|
1992
|
26 |
3 |
p. i-v
|
artikel
|
| 15 |
The Impact of Investigator Heterogeneity in Clinical Trials on Detecting Treatment Differences
|
Peace, Karl E.
|
|
1992
|
26 |
3 |
p. 463-469
|
artikel
|
| 16 |
The Importance of Pharmacokinetic/Toxicokinetic and Metabolic Information in Carcinogenicity Study Design
|
Chasseaud, L. F.
|
|
1992
|
26 |
3 |
p. 445-455
|
artikel
|
| 17 |
The Strategic Approach to Imaging
|
Wilder, James L.
|
|
1992
|
26 |
3 |
p. 395-403
|
artikel
|
| 18 |
The Whys and Wherefores of Statistics in Carcinogenicity Testing
|
Hajian, Gerald
|
|
1992
|
26 |
3 |
p. 361-363
|
artikel
|
| 19 |
Two Demographic Dichotomies: “Black Vs White,” “Left Vs Right”
|
Weissman, Albert
|
|
1992
|
26 |
3 |
p. 351-360
|
artikel
|
| 20 |
Value the US Pharmaceutical Industry Places on Early Dialogue in the Drug Development Process
|
Given, Kenneth M.
|
|
1992
|
26 |
3 |
p. 311-316
|
artikel
|
| 21 |
When Murphy's Law Runs Rampant
|
Padbury, Barbara A. Edge
|
|
1992
|
26 |
3 |
p. 421-423
|
artikel
|
Tijdschrift beschrijving